Investment Rating - The report initiates coverage with a "Buy" rating for the company [4][9]. Core Insights - The company, a subsidiary of the State Grid, is driven by a dual business model of "finance + manufacturing," positioning it to benefit from accelerated investments in the power grid [1][4]. - The carbon asset management business is expected to see sustained high growth due to the establishment of a carbon market framework and increasing trading volumes [2][36]. - The electrical manufacturing segment is poised to benefit from rising investments in distribution networks, with the company being a leader in amorphous transformers [3][46]. Summary by Sections Company Overview - The company is a subsidiary of the State Grid Corporation and has diversified into financial services through significant asset restructuring completed in 2020, which included trust, securities, and futures businesses [1][14]. - In 2024, the company reported total revenue of 11.288 billion yuan, a year-on-year increase of 3.60%, and a net profit attributable to shareholders of 1.574 billion yuan, up 15.39% [1][24]. Carbon Asset Management - The carbon asset management business has shown promising growth, with revenue reaching 0.70 billion yuan in 2024, a 13.39% increase year-on-year, and net profit of 0.10 billion yuan, up 14.51% [2][40]. - The company is the only specialized carbon asset management firm within the State Grid system, focusing on carbon trading and management services [2][40]. Electrical Manufacturing - The company’s subsidiary, ZhiXin Electric, is a leader in amorphous alloy transformers, which are expected to benefit from increasing demand due to their energy efficiency advantages [3][46]. - From 2020 to 2024, ZhiXin Electric's revenue grew from 5.001 billion yuan to 7.375 billion yuan, with a compound annual growth rate (CAGR) of 10%, and net profit increased from 0.16 billion yuan to 1.49 billion yuan, with a CAGR of 75% [3][24]. Financial Forecast and Valuation - The company is projected to achieve revenues of 12.487 billion yuan, 13.908 billion yuan, and 15.578 billion yuan from 2025 to 2027, with year-on-year growth rates of 11%, 11%, and 12% respectively [4][8]. - Net profit is expected to be 1.731 billion yuan, 1.850 billion yuan, and 1.961 billion yuan for the same period, with growth rates of 10%, 7%, and 6% respectively [4][8].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4][9]. Core Views - The company, a subsidiary of the State Grid, is driven by a dual business model of "finance + manufacturing," which positions it to benefit from accelerated investments in the power grid [1][4]. - The carbon asset management business is expected to continue its high growth due to the establishment of a carbon market framework and increasing trading volumes [2][38]. - The electrical manufacturing segment is poised to benefit from rising investments in distribution networks, particularly in amorphous transformers, which are more energy-efficient compared to traditional silicon steel transformers [3][46]. Summary by Sections Company Overview - The company is a subsidiary of the State Grid Corporation and has diversified into financial services through significant asset restructuring completed in 2020, which included trust, securities, and futures businesses [1][14]. - In 2024, the company reported total revenue of 11.288 billion yuan, a year-on-year increase of 3.60%, and a net profit attributable to shareholders of 1.574 billion yuan, up 15.39% [1][24]. Carbon Asset Management - The carbon asset management business has shown promising growth, with revenue reaching 0.70 billion yuan in 2024, reflecting a year-on-year increase of 13.39%, and net profit of 0.10 billion yuan, up 14.51% [2][40]. - The company is the only specialized carbon asset management firm within the State Grid system, focusing on carbon trading and management services [2][40]. Electrical Manufacturing - The company’s subsidiary, ZhiXin Electric, is a leader in the production of amorphous alloy transformers, which are expected to gain market share as distribution network investments increase [3][46]. - From 2020 to 2024, ZhiXin Electric's revenue grew from 5.001 billion yuan to 7.375 billion yuan, with a compound annual growth rate (CAGR) of 10%, and net profit increased from 0.16 billion yuan to 1.49 billion yuan, with a CAGR of 75% [3][24]. Financial Forecast and Valuation - The company is projected to achieve revenues of 12.487 billion yuan, 13.908 billion yuan, and 15.578 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 11%, 11%, and 12% [4][8]. - The expected net profits for the same years are 1.731 billion yuan, 1.850 billion yuan, and 1.961 billion yuan, with growth rates of 10%, 7%, and 6% [4][8].

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Insights - The company slightly exceeded profit expectations in Q1 2025, with revenue reaching 138.30 billion, a year-on-year increase of 16.2%, and operating profit (Non-GAAP) at 40.43 billion, up 7.4% year-on-year [6] - The company is expected to achieve revenue of 624.84 billion, 705.27 billion, and 793.32 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 17.24%, 12.87%, and 12.48% [2] - The company is expanding its overseas investments, which has led to a slight decline in profit margins, with a gross margin of 80.4% in Q1 2025, down 0.8 percentage points year-on-year [6] - The international OTA platform bookings grew over 60% year-on-year, and inbound tourism increased by over 100% [6] - The company is accelerating its AI strategy, which is expected to enhance customer service efficiency significantly [6] Financial Summary - The projected net profit for the company is 169.59 billion, 199.39 billion, and 226.82 billion for 2025, 2026, and 2027 respectively, with a year-on-year change of -0.63%, +17.57%, and +13.75% [2] - The earnings per share (EPS) are forecasted to be 23.77, 27.94, and 31.79 for 2025, 2026, and 2027 respectively [2] - The company’s total assets are expected to reach 275.05 billion, 297.69 billion, and 329.00 billion for 2025, 2026, and 2027 respectively [7]

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The company's Q1 2025 profit slightly exceeded expectations, with revenue reaching 138.30 billion, a year-on-year increase of 16.2%, and operating profit (Non-GAAP) at 40.43 billion, up 7.4% year-on-year [6] - The company is expected to achieve revenue of 624.84 billion, 705.27 billion, and 793.32 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 17.24%, 12.87%, and 12.48% [2] - The company is expanding its overseas investments, contributing to revenue growth, with international OTA platform bookings increasing over 60% year-on-year [6] - The company is accelerating its AI strategy, which is expected to enhance customer service efficiency significantly [6] Financial Summary - The forecasted revenue and net profit for the company from 2025 to 2027 are as follows: - Revenue: 624.84 billion (2025), 705.27 billion (2026), 793.32 billion (2027) - Net Profit: 169.59 billion (2025), 199.39 billion (2026), 226.82 billion (2027) [2][7] - The company's earnings per share (EPS) is projected to be 23.77 yuan in 2025, 27.94 yuan in 2026, and 31.79 yuan in 2027 [2][7] - The price-to-earnings (P/E) ratio is expected to be 19X in 2025, 16X in 2026, and 14X in 2027 [2]

Market Overview - On May 26, the Shanghai Composite Index decreased by 0.05%, the CSI 300 fell by 0.57%, the STAR 50 rose by 0.17%, the CSI 1000 increased by 0.65%, the ChiNext Index dropped by 0.8%, and the Hang Seng Index declined by 1.35% [4][3] - The best-performing sectors on May 26 were Media (+2.14%), Computer (+1.39%), Environmental Protection (+1.22%), Communication (+1.1%), and Light Industry Manufacturing (+1.04%). The worst-performing sectors were Automotive (-1.78%), Pharmaceutical Biology (-1.08%), Comprehensive (-0.86%), Banking (-0.75%), and Home Appliances (-0.71%) [4][3] - The total trading volume for the entire A-share market on May 26 was 1,033.9 billion yuan, with a net outflow of 1.507 billion Hong Kong dollars from southbound funds [4][3] Key Insights - From the production side, high-frequency indicators for the service and industrial sectors remained generally stable compared to the previous week. On the demand side, there was a divergence in variables, with consumption strengthening, fixed asset investment showing mixed strength, and exports showing signs of recovery [5] - Price-wise, marginal pressure on prices was observed this week, with a systemic rebound dependent on a demand-side recovery. Following the China-US trade talks, the fundamental pressure has eased [5]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [7] Core Views - The company is expected to achieve revenue growth driven by new product launches, international expansion, and innovation in drug development. The anesthetic pipeline continues to evolve, with several high-barrier products approved for market entry, which is anticipated to enhance the company's competitive edge in the anesthetic and analgesic sectors [10][12] Summary by Relevant Sections Growth Capability - In 2024, the company's chemical preparations generated revenue of 1.077 billion yuan, a year-over-year increase of 22.25%. Chemical raw materials achieved revenue of 121 million yuan, up 28.65%. CMO/CDMO services saw revenue of 65 million yuan, a significant increase of 111.59%. The company has undertaken 23 CMO/CDMO projects, indicating strong growth potential from new product launches and international business expansion [2] - The company plans to launch at least 10 generic drug products and submit at least 10 new product applications in 2025, which is expected to contribute to revenue growth in the coming years [2] Internationalization of Formulations - The company received FDA approval for its Nicardipine Hydrochloride Injection in September 2024, marking its first shipment to the U.S. market. The company is gradually expanding its international product offerings, with several ANDA applications submitted for various products [3] Competitive Position in Anesthesia - As of 2024, the company has launched 16 products in the anesthetic and analgesic fields, with over 20 in development. The market share for key products is strong, with the company's Nalmefene Hydrochloride Injection holding a 61.73% market share. Newly approved high-barrier products are expected to drive revenue growth [4] - The company is advancing its high-end generic drugs, improved new drugs, and innovative drugs in the anesthetic and analgesic sectors, which will help establish its brand and enhance core competitiveness [4] Innovation and R&D Acceleration - The company is accelerating its transition from generic to innovative drug development, with R&D expenditures exceeding 20% of revenue in 2024. Investment in innovative drugs accounts for nearly 30% of R&D spending, indicating a strong commitment to innovation [5] Financial Performance - In 2024, the company achieved revenue of 1.35 billion yuan, a year-over-year increase of 20.82%, with a net profit of 238 million yuan, up 5.15%. The net profit margin after excluding stock incentive expenses showed a stable growth trend [10][12] - The overall gross margin for 2024 was 74.93%, a decrease of 5.08 percentage points, primarily due to declines in the gross margins of technical services, CMO/CDMO, and raw materials [11] Earnings Forecast and Valuation - The company is projected to achieve EPS of 1.56, 1.83, and 2.19 yuan per share for 2025, 2026, and 2027, respectively. The current closing price corresponds to a PE ratio of 22 times for 2025 [12]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Viewpoints - The company is expected to see a turning point in its domestic business in 2025 due to the anticipated recovery in local special bonds and monthly bidding for various medical devices. The international market is projected to grow significantly, driven by the company's high-end customer base and balanced revenue distribution across major regions, particularly in developing countries and Europe [1][2] - The company’s revenue from the life information and support segment decreased by 11.1% in 2024, while the minimally invasive surgery business grew over 30%. The international life information and support business achieved double-digit growth [2] - The in-vitro diagnostics segment saw a revenue increase of 10.8% in 2024, with international business growing over 30%. The company ranked third in the domestic market for chemiluminescence and surpassed 15% market share in biochemical business [3] - The medical imaging segment's revenue grew by 6.6% in 2024, with international business growing over 15%. The high-end ultrasound system Resona A20 generated over 400 million yuan in its first year [3] - The company's gross margin was 63.1% in 2024, a decrease of 3.0 percentage points year-on-year, while the net profit margin was 32.0%, down 1.2 percentage points [4] - The company is expected to maintain stable growth from 2025 to 2027, driven by the global medical infrastructure wave and expansion in high-end markets [5] Financial Summary - The company's revenue for 2024 is projected at 36,726 million yuan, with a year-on-year growth of 5.14%. By 2027, revenue is expected to reach 52,497 million yuan, reflecting a growth rate of 14.72% [12] - The net profit attributable to the parent company for 2024 is estimated at 11,668 million yuan, with a slight increase of 0.74% year-on-year. By 2027, it is projected to reach 16,943 million yuan, growing at 15.53% [12] - The earnings per share (EPS) for 2024 is expected to be 9.62 yuan, increasing to 13.97 yuan by 2027 [12]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to see a turning point in its domestic business in 2025 due to the anticipated recovery in local special bonds and monthly bidding for various medical devices, despite short-term impacts from tight local finances and delays in regular tenders [1] - The international market is projected to grow significantly, driven by the company's continued penetration into high-end customer segments and balanced revenue distribution across major global regions, particularly in developing countries and Europe [1] - The company is expected to maintain steady long-term growth, supported by the global medical infrastructure wave and expansion into high-end markets [5] Business Segmentation and Highlights - **Life Information and Support Segment**: Revenue decreased by 11.1% in 2024, with minimally invasive surgery business growing over 30%. Internationally, this segment achieved double-digit growth [2] - **In Vitro Diagnostics Segment**: Revenue grew by 10.8% in 2024, surpassing the Life Information and Support segment for the first time. Internationally, this segment saw growth exceeding 30% [3] - **Medical Imaging Segment**: Revenue increased by 6.6% in 2024, with international business growing over 15%. The high-end ultrasound system Resona A20 generated over 400 million yuan in its first year [3] Profitability Analysis - The company's gross margin for 2024 was 63.1%, a decrease of 3.0 percentage points year-on-year, while the net profit margin was 32.0%, down 1.2 percentage points [4] - Operating cash flow for 2024 was 12.43 billion yuan, a year-on-year increase of 12.4%, representing 102.8% of net operating income [4] - Profitability is expected to improve slightly from 2025 to 2027, driven by an increase in high-end product sales and stable operating expense ratios [4] Financial Forecast and Valuation - The company is projected to maintain stable growth from 2025 to 2027, with expected revenues of 40.33 billion yuan in 2025, 45.76 billion yuan in 2026, and 52.50 billion yuan in 2027, reflecting growth rates of 9.82%, 13.46%, and 14.72% respectively [12] - The estimated earnings per share (EPS) for 2025 is 10.61 yuan, with a price-to-earnings (P/E) ratio of 21.86 [10][12]

Investment Rating - The industry investment rating is optimistic, with a recommendation to buy [3][19]. Core Insights - The report highlights the production elasticity and profit elasticity of electrolytic aluminum companies, indicating that profitability will be a key competitive factor due to fixed production capacity [8]. - The report predicts a decrease in the volatility of alumina prices in 2025, which will enhance the profitability of companies like Yun Aluminum, Shenhuo, and Tianshan [8]. - The report provides forecasts for gold production from listed companies, with specific attention to the CAGR of production from 2024 to 2027 [10][11]. Summary by Sections Copper Industry - The report includes production data and forecasts for major copper companies, emphasizing the importance of proprietary mining data [6]. Electrolytic Aluminum - The report details the production capacity and market valuation of various electrolytic aluminum companies, noting that the lowest market value per ton of aluminum is approximately 21,000 RMB [8][9]. Gold Industry - The report presents a forecast of self-produced gold output for listed companies, with specific figures for total gold resources and market capitalization [10][11]. Lithium Industry - The report outlines the lithium resource rights and production forecasts for several companies, highlighting significant growth rates for companies like Ganfeng Lithium and Yongxing Materials [12]. Uranium Industry - The report discusses the production forecasts for uranium companies, particularly focusing on China General Nuclear Power Corporation, with a projected CAGR of 8.16% from 2024 to 2027 [14][15].

证券研究报告 钢铁周报：铁水顶部信号明显，但行业基本面仍健康 行业评级：看好 2025 年 05 月 26 日 | 分析师 | 沈皓俊 | 研究助理 | 张轩 | | --- | --- | --- | --- | | 邮箱 | shenhaojun@stocke.com.cn | 邮箱 | zhangxuan01@stocke.com.cn | | 证书编号 | S1230523080011 | | | 价格 | | 【浙商金属 沈皓俊】 | | 钢铁周度数据 | | | （2025年5月25日） | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 价格 | | | | 周涨跌幅 | | 年初至今涨跌幅 | | | | 上证指数 | | 3 , | 348 | -0 . | 6% | -0 . | 1% | | | 沪深300 | | 3 , | 882 | -0 . | 2% | -1 . | 3% | | 板 | SW钢铁指数 | | 2 , | 139 | -0 . | 9% | 1 . | 8% | | 块 | | SW ...